Evidence map›Paper›PMID 37692459›Full record

ArticleJournal of central nervous system disease2023

Lidocaine as a potential therapeutic option for super-refractory status epilepticus: A case report.

Mayu Sugata, Hiroshi Kataoka, Yuto Uchihara, Daisuke Shimada, Kazuaki Atagi, Michitaka Nakamura, Makoto Hara, Makoto Kawahara, Kazuma Sugie

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of central nervous system disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Febrile infection-related epilepsy syndrome (FIRES) in adults: a case report and review of factors associated with survival.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Mayu SugataDepartment of Neurology, Nara Medical University, Kashihara, Japan.ORCID https://orcid.org/0000-0003-3655-442X
Hiroshi KataokaDepartment of Neurology, Nara Medical University, Kashihara, Japan.ORCID https://orcid.org/0000-0002-4157-5447
Yuto UchiharaDepartment of Neurology, Nara Prefecture General Medical Center, Nara, Japan.
Daisuke ShimadaDepartment of Neurology, Nara Medical University, Kashihara, Japan.
Kazuaki AtagiDepartment of Intensive Care Unit, Nara Prefecture General Medical Center, Nara, Japan.
Michitaka NakamuraDepartment of Intensive Care Unit, Nara Prefecture General Medical Center, Nara, Japan.
Makoto HaraDepartment of Neurology, Nihon University School of Medicine, Itabashi-ku, Japan.
Makoto KawaharaDepartment of Neurology, Nara Prefecture General Medical Center, Nara, Japan.
Kazuma SugieDepartment of Neurology, Nara Medical University, Kashihara, Japan.ORCID https://orcid.org/0000-0003-0148-4687
Nara Medical University · JPNara Prefecture General Medical CenterNihon University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New-onset refractory status epilepticus (NORSE) is a rare and devastating condition and the prognosis is often poor, with half to two-thirds of survivors experiencing drug-resistant epilepsy, residual cognitive impairment, or functional disability, and the mortality rate is 16% to 27% for adults. We describe a patient with cryptogenic NORSE and favorable recovery from drug-resistant super-refractory SE after the use of intravenous lidocaine. The patient experienced fever and presented with refractory generalized tonic-clonic seizures. The cause was not found by performing extensive examinations, including cell surface autoantibodies and rat brain immunohistochemistry evaluations. The refractory SE with unresponsiveness to multiple anti-epileptic and prolonged sedative medications, which are necessary for prolonged mechanical ventilation, were ameliorated by additive treatment with intravenous lidocaine initiating at 1 mg/kg/h and maintaining at 2 mg/kg/h for 40 days, which led to freedom from intravenous sedative medication and mechanical ventilation. The patient was able to return to school. Lidocaine may be an optional treatment for cryptogenic NORSE.

Indexed as

epilepsylidocaineNew-onset refractory status epilepticusstatus epilepticustherapy

Identifiers

PMID37692459
PMCPMC10492485
OpenAlexW4386531890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.